Claims for Patent: 9,561,244

Summary for Patent: 9,561,244

Title:	Anti-neoplastic compositions comprising extracts of black cohosh
Abstract:	A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na.sup.+K.sup.+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.
Inventor(s):	Einbond; Linda Saxe (Crestwood, NY)
Assignee:	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY)
Application Number:	13/374,496
Patent Claims:	1. A method for treating a neoplasia in a human, comprising administering to the human an amount of actein effective to treat the neoplasia and an effective anti-neoplastic amount of at least one additional chemotherapeutic agent, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, 5-fluorouracil, herceptin, paclitaxel, and tamoxifen, wherein the amount of actein is about 0.2 .mu.g/ml to 20.0 .mu.g/ml; and wherein the amount of cisplatin is about 2 .mu.g/ml to 20 .mu.g/ml, the amount of doxorubicin is about 0.02 .mu.g/ml to 0.2 .mu.g/ml, the amount of 5-fluorouracil is about 0.002 .mu.g/ml to 0.2 .mu.g/ml, the amount of herceptin is about 0.8 .mu.g/ml to 32 .mu.g/ml, the amount of tamoxifen is about 2 .mu.g/ml to 50 .mu.g/ml, and the amount of paclitaxel is about 0.5 nM to 5 nM. 2. The method of claim 1, wherein the neoplasia is a carcinoma, a lymphocytic leukemia, a myeloid leukemia, a malignant lymphoma, a malignant melanoma, a myeloproliferative disease, a sarcoma, a brain tumor, a childhood tumor, or a mixed type of neoplasia. 3. The method of claim 2, wherein the carcinoma is a breast carcinoma or a colon carcinoma. 4. The method of claim 1, wherein the chemotherapeutic agent is paclitaxel, wherein the amount of actein is between about 0.5 .mu.g/ml to about 5 .mu.g/ml, and the amount of paclitaxel is between about 0.5 nM to about 5 nM. 5. The method of claim 1, wherein the chemotherapeutic agent is herceptin, wherein the amount of actein is between about 0.2 .mu.g/ml to about 2 .mu.g/ml, and the amount of herceptin is about 8 .mu.g/ml to 32 .mu.g/ml.

Details for Patent 9,561,244

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2022-12-27
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2022-12-27